GLOBAL BONE MARROW TRANSPLANT MARKET FORECAST 2018-2026
KEY FINDINGS
Propelled by the growing prevalence of cancer and huge funding for regenerative medicines by the federal government, the global bone marrow transplant market is expected to rise with a CAGR of 5.45% over the forecast period of 2018-2026.
MARKET INSIGHTS
The global bone marrow transplant market is segmented on the basis of end-users, indications and transplant type. The end-users for this market are hospitals, multi-specialty clinics and ambulatory surgical centres. The indications segment of the bone marrow transplant market includes acute leukaemia, multiple myelomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, solid tumours and other indications. The market by transplant type is segmented into allogenic bone marrow transplant and autologous bone marrow transplant.
REGIONAL INSIGHTS
The regional segmentation of the global bone marrow transplant market is done into Europe, Asia-Pacific, North America and rest of the world. The Asia-Pacific bone marrow transplant market is anticipated to progress with the fastest CAGR over the forecast period. Growing investments in public and private sectors to cater to the needs of the medical needs of the ever-growing population in China and India are contributing to the market growth in this region. However, a major chunk of the global market share is expected to be captured by the European bone marrow transplant market. The region is witnessing increasing cases of breast, prostate and colorectal cancer. Also, the government in UK and Spain are encouraging proactive policies to increase the market demand in this region.
COMPETITIVE INSIGHTS
Some of the key companies engaged in the bone marrow transplant market are Affymetrix Inc. (Acquired By Thermofisher), Abbott Laboratories, Agendia N.V, Ambrilia Biopharma Inc, Agilent Technologies Inc, Astellas Pharma Inc, Diadexus Inc. (Acquired By Diazyme Laboratories), Qiagen N.V, Illumina Inc, Roche Diagnostics Ltd, Sanofi and Stryker Corporation.
Propelled by the growing prevalence of cancer and huge funding for regenerative medicines by the federal government, the global bone marrow transplant market is expected to rise with a CAGR of 5.45% over the forecast period of 2018-2026.
MARKET INSIGHTS
The global bone marrow transplant market is segmented on the basis of end-users, indications and transplant type. The end-users for this market are hospitals, multi-specialty clinics and ambulatory surgical centres. The indications segment of the bone marrow transplant market includes acute leukaemia, multiple myelomas, Hodgkin lymphoma, Non-Hodgkin lymphoma, solid tumours and other indications. The market by transplant type is segmented into allogenic bone marrow transplant and autologous bone marrow transplant.
REGIONAL INSIGHTS
The regional segmentation of the global bone marrow transplant market is done into Europe, Asia-Pacific, North America and rest of the world. The Asia-Pacific bone marrow transplant market is anticipated to progress with the fastest CAGR over the forecast period. Growing investments in public and private sectors to cater to the needs of the medical needs of the ever-growing population in China and India are contributing to the market growth in this region. However, a major chunk of the global market share is expected to be captured by the European bone marrow transplant market. The region is witnessing increasing cases of breast, prostate and colorectal cancer. Also, the government in UK and Spain are encouraging proactive policies to increase the market demand in this region.
COMPETITIVE INSIGHTS
Some of the key companies engaged in the bone marrow transplant market are Affymetrix Inc. (Acquired By Thermofisher), Abbott Laboratories, Agendia N.V, Ambrilia Biopharma Inc, Agilent Technologies Inc, Astellas Pharma Inc, Diadexus Inc. (Acquired By Diazyme Laboratories), Qiagen N.V, Illumina Inc, Roche Diagnostics Ltd, Sanofi and Stryker Corporation.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF GEOGRAPHY
3.2.2. SOLID TUMORS ARE THE FASTEST GROWING INDICATION IN THE BONE MARROW TRANSPLANT MARKET
3.2.3. AUTOLOGOUS BONE MARROW TRANSPLANT TYPE DOMINATES THE BONE MARROW TRANSPLANT MARKET
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASED PREVALENCE OF CANCER
4.1.2. INCREASE IN FEDERAL FUNDING IN REGENERATIVE MEDICINES
4.2. MARKET RESTRAINTS
4.2.1. SCARCITY OF DONORS AND ITS GENETICAL ACCEPTANCE
4.2.2. ETHICAL ISSUES
4.3. MARKET OPPORTUNITIES
4.3.1. RISE IN REIMBURSEMENT FOR SURGERIES IN DEVELOPED NATIONS
4.3.2. TECHNOLOGICAL INNOVATIONS
4.4. MARKET CHALLENGES
4.4.1. HIGH COST OF TREATMENT
5. MARKET SEGMENTATION
5.1. MARKET BY TRANSPLANT TYPE 2018-2026
5.1.1. AUTOLOGOUS BONE MARROW TRANSPLANT
5.1.2. ALLOGENEIC BONE MARROW TRANSPLANT
5.2. MARKET BY INDICATION 2018-2026
5.2.1. MULTIPLE MYELOMA
5.2.2. ACUTE LEUKEMIA
5.2.3. HODGKIN LYMPHOMA
5.2.4. NON-HODGKIN LYMPHOMA
5.2.5. SOLID TUMORS
5.2.6. OTHER INDICATION
5.3. MARKET BY END USER 2018-2026
5.3.1. MULTISPECIALTY CLINICS
5.3.2. HOSPITALS
5.3.3. AMBULATORY SURGICAL CENTERS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. KEY MARKET TRENDS
6.2.1. NEWER APPLICATION OF BONE MARROW TRANSPLANT
6.2.2. ONLINE SERVICES
6.3. KEY BUYING CRITERIA
6.3.1. HIGH PRICE
6.3.2. EFFICACY
6.3.3. APPLICATION AND EFFECTIVENESS
6.3.4. ACCURACY
6.4. OPPORTUNITY MATRIX
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UNITED KINGDOM (UK)
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. CHINA
7.3.2. INDIA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. REST OF ASIA-PACIFIC
7.4. REST OF THE WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND AFRICA (MEA)
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SCOT ANALYSIS
8.1.4. STRATEGIC INITIATIVES
8.2. AFFYMETRIX, INC. (ACQUIRED BY THERMOFISHER)
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SCOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. AGENDIA N.V.
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SCOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. AGILENT TECHNOLOGIES, INC.
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. AMBRILIA BIOPHARMA INC.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVES
8.6. ASTELLAS PHARMA INC.
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC INITIATIVES
8.7. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. ILLUMINA, INC.
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. QIAGEN N.V.
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE DIAGNOSTICS LTD
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANOFI
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCTS PORTFOLIO
8.11.3. SWOT ANALYSIS
8.11.4. STRATEGIC INITIATIVES
8.12. STRYKER CORPORATION
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
TABLE LIST
TABLE 1 GLOBAL BONE MARROW MARKET TRANSPLANT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 GLOBAL BONE MARROW TRANSPLANT MARKET BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 3 GLOBAL BONE MARROW TRANSPLANT MARKET BY INDICATION 2018-2026 ($ MILLION)
TABLE 4 GLOBAL BONE MARROW TRANSPLANT MARKET IN MULTIPLE MYELOMA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 5 GLOBAL BONE MARROW TRANSPLANT MARKET IN ACUTE LEUKEMIA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 6 GLOBAL BONE MARROW TRANSPLANT MARKET IN HODGKIN LYMPHOMA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 7 GLOBAL BONE MARROW TRANSPLANT MARKET IN NON-HODGKIN LYMPHOMA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 8 GLOBAL BONE MARROW TRANSPLANT MARKET IN SOLID TUMORS BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 9 GLOBAL BONE MARROW TRANSPLANT MARKET, BY GEOGRAPHY 2018-2026($ MILLION)
TABLE 10 NORTH AMERICA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
TABLE 11 EUROPE BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
TABLE 12 ASIA-PACIFIC BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
TABLE 13 REST OF WORLD BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. EUROPE CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF GEOGRAPHY
3.2.2. SOLID TUMORS ARE THE FASTEST GROWING INDICATION IN THE BONE MARROW TRANSPLANT MARKET
3.2.3. AUTOLOGOUS BONE MARROW TRANSPLANT TYPE DOMINATES THE BONE MARROW TRANSPLANT MARKET
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. INCREASED PREVALENCE OF CANCER
4.1.2. INCREASE IN FEDERAL FUNDING IN REGENERATIVE MEDICINES
4.2. MARKET RESTRAINTS
4.2.1. SCARCITY OF DONORS AND ITS GENETICAL ACCEPTANCE
4.2.2. ETHICAL ISSUES
4.3. MARKET OPPORTUNITIES
4.3.1. RISE IN REIMBURSEMENT FOR SURGERIES IN DEVELOPED NATIONS
4.3.2. TECHNOLOGICAL INNOVATIONS
4.4. MARKET CHALLENGES
4.4.1. HIGH COST OF TREATMENT
5. MARKET SEGMENTATION
5.1. MARKET BY TRANSPLANT TYPE 2018-2026
5.1.1. AUTOLOGOUS BONE MARROW TRANSPLANT
5.1.2. ALLOGENEIC BONE MARROW TRANSPLANT
5.2. MARKET BY INDICATION 2018-2026
5.2.1. MULTIPLE MYELOMA
5.2.2. ACUTE LEUKEMIA
5.2.3. HODGKIN LYMPHOMA
5.2.4. NON-HODGKIN LYMPHOMA
5.2.5. SOLID TUMORS
5.2.6. OTHER INDICATION
5.3. MARKET BY END USER 2018-2026
5.3.1. MULTISPECIALTY CLINICS
5.3.2. HOSPITALS
5.3.3. AMBULATORY SURGICAL CENTERS
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCES ANALYSIS
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTES
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. THREAT OF RIVALRY
6.2. KEY MARKET TRENDS
6.2.1. NEWER APPLICATION OF BONE MARROW TRANSPLANT
6.2.2. ONLINE SERVICES
6.3. KEY BUYING CRITERIA
6.3.1. HIGH PRICE
6.3.2. EFFICACY
6.3.3. APPLICATION AND EFFECTIVENESS
6.3.4. ACCURACY
6.4. OPPORTUNITY MATRIX
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
7.2. EUROPE
7.2.1. THE UNITED KINGDOM (UK)
7.2.2. FRANCE
7.2.3. GERMANY
7.2.4. SPAIN
7.2.5. ITALY
7.2.6. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. CHINA
7.3.2. INDIA
7.3.3. JAPAN
7.3.4. SOUTH KOREA
7.3.5. REST OF ASIA-PACIFIC
7.4. REST OF THE WORLD
7.4.1. LATIN AMERICA
7.4.2. MIDDLE EAST AND AFRICA (MEA)
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. COMPANY OVERVIEW
8.1.2. PRODUCT PORTFOLIO
8.1.3. SCOT ANALYSIS
8.1.4. STRATEGIC INITIATIVES
8.2. AFFYMETRIX, INC. (ACQUIRED BY THERMOFISHER)
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. SCOT ANALYSIS
8.2.4. STRATEGIC INITIATIVES
8.3. AGENDIA N.V.
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SCOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. AGILENT TECHNOLOGIES, INC.
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. SCOT ANALYSIS
8.4.4. STRATEGIC INITIATIVES
8.5. AMBRILIA BIOPHARMA INC.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVES
8.6. ASTELLAS PHARMA INC.
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. SCOT ANALYSIS
8.6.4. STRATEGIC INITIATIVES
8.7. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. ILLUMINA, INC.
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. QIAGEN N.V.
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS
8.9.4. STRATEGIC INITIATIVES
8.10. ROCHE DIAGNOSTICS LTD
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.10.3. SCOT ANALYSIS
8.10.4. STRATEGIC INITIATIVES
8.11. SANOFI
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCTS PORTFOLIO
8.11.3. SWOT ANALYSIS
8.11.4. STRATEGIC INITIATIVES
8.12. STRYKER CORPORATION
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
TABLE LIST
TABLE 1 GLOBAL BONE MARROW MARKET TRANSPLANT MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 2 GLOBAL BONE MARROW TRANSPLANT MARKET BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 3 GLOBAL BONE MARROW TRANSPLANT MARKET BY INDICATION 2018-2026 ($ MILLION)
TABLE 4 GLOBAL BONE MARROW TRANSPLANT MARKET IN MULTIPLE MYELOMA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 5 GLOBAL BONE MARROW TRANSPLANT MARKET IN ACUTE LEUKEMIA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 6 GLOBAL BONE MARROW TRANSPLANT MARKET IN HODGKIN LYMPHOMA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 7 GLOBAL BONE MARROW TRANSPLANT MARKET IN NON-HODGKIN LYMPHOMA BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 8 GLOBAL BONE MARROW TRANSPLANT MARKET IN SOLID TUMORS BY TRANSPLANT TYPE 2018-2026 ($ MILLION)
TABLE 9 GLOBAL BONE MARROW TRANSPLANT MARKET, BY GEOGRAPHY 2018-2026($ MILLION)
TABLE 10 NORTH AMERICA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
TABLE 11 EUROPE BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
TABLE 12 ASIA-PACIFIC BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
TABLE 13 REST OF WORLD BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURES LIST
FIGURE 1 BONE MARROW BLOOD COMPONENTS
FIGURE 2 GLOBAL BONE MARROW MARKET TRANSPLANT 2018-2026 ($ MILLION)
FIGURE 3 DIFFERENT TYPES OF CANCERS MANAGED BY BONE MARROW TRANSPLANT
FIGURE 4 ETHICAL ISSUES REQUIREMENTS IN BONE MARROW TRANSPLANT
FIGURE 5 PHASES IN BONE MARROW TRANSPLANT
FIGURE 6 GLOBAL BONE MARROW TRANSPLANT MARKET IN AUTOLOGOUS BONE MARROW TRANSPLANT 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL BONE MARROW TRANSPLANT MARKET IN ALLOGENIC BONE MARROW TRANSPLANT 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL BONE MARROW TRANSPLANT MARKET IN MULTIPLE MYELOMA 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL BONE MARROW TRANSPLANT MARKET IN ACUTE LEUKEMIA 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL BONE MARROW TRANSPLANT MARKET IN HODGKIN LYMPHOMA 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL BONE MARROW TRANSPLANT MARKET IN NON-HODGKIN LYMPHOMA 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL BONE MARROW TRANSPLANT MARKET IN SOLID TUMORS 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL BONE MARROW TRANSPLANT MARKET IN OTHER INDICATION 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL BONE MARROW TRANSPLANT MARKET IN MULTISPECIALTY CLINICS 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL BONE MARROW TRANSPLANT MARKET IN HOSPITALS 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL BONE MARROW TRANSPLANT MARKET IN AMBULATORY SURGICAL CENTERS 2018-2026 ($ MILLION)
FIGURE 17 UNITED STATES BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 18 CANADA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 19 PERCENTAGE VISE DISTRIBUTION OF VARIOUS CANCERS ENGLAND (2016)
FIGURE 20 THE UNITED KINGDOM BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 21 FRANCE BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 22 GERMANY BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 23 SPAIN BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 24 ITALY BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 25 REST OF EUROPE BIOMARKERS MARKET 2018-2026 ($ MILLION)
FIGURE 26 CHINA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 27 INDIA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 28 JAPAN BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 29 SOUTH KOREA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 30 REST OF ASIA-PACIFIC BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 31 LATIN AMERICA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. AFFYMETRIX, INC. (ACQUIRED BY THERMOFISHER)
3. AGENDIA N.V.
4. AGILENT TECHNOLOGIES, INC.
5. AMBRILIA BIOPHARMA INC.
6. ASTELLAS PHARMA INC.
7. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
8. ILLUMINA, INC.
9. QIAGEN N.V.
10. ROCHE DIAGNOSTICS LTD
11. SANOFI
12. STRYKER CORPORATION
FIGURE 1 BONE MARROW BLOOD COMPONENTS
FIGURE 2 GLOBAL BONE MARROW MARKET TRANSPLANT 2018-2026 ($ MILLION)
FIGURE 3 DIFFERENT TYPES OF CANCERS MANAGED BY BONE MARROW TRANSPLANT
FIGURE 4 ETHICAL ISSUES REQUIREMENTS IN BONE MARROW TRANSPLANT
FIGURE 5 PHASES IN BONE MARROW TRANSPLANT
FIGURE 6 GLOBAL BONE MARROW TRANSPLANT MARKET IN AUTOLOGOUS BONE MARROW TRANSPLANT 2018-2026 ($ MILLION)
FIGURE 7 GLOBAL BONE MARROW TRANSPLANT MARKET IN ALLOGENIC BONE MARROW TRANSPLANT 2018-2026 ($ MILLION)
FIGURE 8 GLOBAL BONE MARROW TRANSPLANT MARKET IN MULTIPLE MYELOMA 2018-2026 ($ MILLION)
FIGURE 9 GLOBAL BONE MARROW TRANSPLANT MARKET IN ACUTE LEUKEMIA 2018-2026 ($ MILLION)
FIGURE 10 GLOBAL BONE MARROW TRANSPLANT MARKET IN HODGKIN LYMPHOMA 2018-2026 ($ MILLION)
FIGURE 11 GLOBAL BONE MARROW TRANSPLANT MARKET IN NON-HODGKIN LYMPHOMA 2018-2026 ($ MILLION)
FIGURE 12 GLOBAL BONE MARROW TRANSPLANT MARKET IN SOLID TUMORS 2018-2026 ($ MILLION)
FIGURE 13 GLOBAL BONE MARROW TRANSPLANT MARKET IN OTHER INDICATION 2018-2026 ($ MILLION)
FIGURE 14 GLOBAL BONE MARROW TRANSPLANT MARKET IN MULTISPECIALTY CLINICS 2018-2026 ($ MILLION)
FIGURE 15 GLOBAL BONE MARROW TRANSPLANT MARKET IN HOSPITALS 2018-2026 ($ MILLION)
FIGURE 16 GLOBAL BONE MARROW TRANSPLANT MARKET IN AMBULATORY SURGICAL CENTERS 2018-2026 ($ MILLION)
FIGURE 17 UNITED STATES BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 18 CANADA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 19 PERCENTAGE VISE DISTRIBUTION OF VARIOUS CANCERS ENGLAND (2016)
FIGURE 20 THE UNITED KINGDOM BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 21 FRANCE BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 22 GERMANY BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 23 SPAIN BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 24 ITALY BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 25 REST OF EUROPE BIOMARKERS MARKET 2018-2026 ($ MILLION)
FIGURE 26 CHINA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 27 INDIA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 28 JAPAN BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 29 SOUTH KOREA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 30 REST OF ASIA-PACIFIC BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 31 LATIN AMERICA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA BONE MARROW TRANSPLANT MARKET 2018-2026 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. AFFYMETRIX, INC. (ACQUIRED BY THERMOFISHER)
3. AGENDIA N.V.
4. AGILENT TECHNOLOGIES, INC.
5. AMBRILIA BIOPHARMA INC.
6. ASTELLAS PHARMA INC.
7. DIADEXUS INC. (ACQUIRED BY DIAZYME LABORATORIES)
8. ILLUMINA, INC.
9. QIAGEN N.V.
10. ROCHE DIAGNOSTICS LTD
11. SANOFI
12. STRYKER CORPORATION
